Tags

Type your tag names separated by a space and hit enter

Changes in androgens during treatment with four low-dose contraceptives.
Contraception. 1996 Mar; 53(3):171-6.C

Abstract

The aim of the present study was to compare changes in the endogenous androgen environment in healthy women while on low-dose oral contraceptives (OCs). One-hundred healthy women were randomized to receive one of four OCs during six months: 21 tablets of Cilest, Femodeen, Marvelon, or Mercilon. During the luteal phase of the pretreatment cycle, body weight and blood pressure were recorded and the following parameters were measured: sex hormone-binding globulin (SHBG), corticosteroid-binding globulin (CBG), testosterone (T), free testosterone (FT), 5 alpha-dihydrotestosterone (DHT), androstenedione (A), dehydroepiandrosterone-sulphate (DHEA-S) and 17 alpha-hydroxyprogesterone (170HP) while also the free androgen index (FAI) was calculated. Measurements were repeated during the 3rd week of pill intake in the 4th and the 6th pill month. There were no differences on body mass and blood pressure with the use of the four OCs. The mean serum DHEA-S decreased significantly in all groups though less in the Mercilon group when compared to Cilest and Marvelon (approximately 20% vs 45%). Mean serum SHBG and CBG increased significantly in all four groups approximately 250% and 100%, respectively. In each group CBG also increased significantly but less in women taking Mercilon (-75%) as compared to the others (-100%). Current low-dose OCs were found to have similar impact on the endogenous androgen metabolism with significant decreases of serum testosterone, DHT, A, and DHEA-S. They may be equally beneficial in women with androgen related syndromes such as acne and hirsutism.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, University Hospital Nijmegen St. Radboud, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

8689882

Citation

Coenen, C M., et al. "Changes in Androgens During Treatment With Four Low-dose Contraceptives." Contraception, vol. 53, no. 3, 1996, pp. 171-6.
Coenen CM, Thomas CM, Borm GF, et al. Changes in androgens during treatment with four low-dose contraceptives. Contraception. 1996;53(3):171-6.
Coenen, C. M., Thomas, C. M., Borm, G. F., Hollanders, J. M., & Rolland, R. (1996). Changes in androgens during treatment with four low-dose contraceptives. Contraception, 53(3), 171-6.
Coenen CM, et al. Changes in Androgens During Treatment With Four Low-dose Contraceptives. Contraception. 1996;53(3):171-6. PubMed PMID: 8689882.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Changes in androgens during treatment with four low-dose contraceptives. AU - Coenen,C M, AU - Thomas,C M, AU - Borm,G F, AU - Hollanders,J M, AU - Rolland,R, PY - 1996/3/1/pubmed PY - 1996/3/1/medline PY - 1996/3/1/entrez KW - Acne KW - Androgens KW - Arab Countries KW - Asia KW - Biology KW - Comparative Studies KW - Contraception KW - Contraceptive Methods KW - Dermatitis KW - Developed Countries KW - Developing Countries KW - Diseases KW - Endocrine System KW - Europe KW - Family Planning KW - Hirsutism KW - Hormones KW - Netherlands KW - Oral Contraceptives KW - Oral Contraceptives, Low-dose KW - Physiology KW - Research Methodology KW - Research Report KW - Saudi Arabia KW - Signs And Symptoms KW - Studies KW - Western Asia KW - Western Europe SP - 171 EP - 6 JF - Contraception JO - Contraception VL - 53 IS - 3 N2 - The aim of the present study was to compare changes in the endogenous androgen environment in healthy women while on low-dose oral contraceptives (OCs). One-hundred healthy women were randomized to receive one of four OCs during six months: 21 tablets of Cilest, Femodeen, Marvelon, or Mercilon. During the luteal phase of the pretreatment cycle, body weight and blood pressure were recorded and the following parameters were measured: sex hormone-binding globulin (SHBG), corticosteroid-binding globulin (CBG), testosterone (T), free testosterone (FT), 5 alpha-dihydrotestosterone (DHT), androstenedione (A), dehydroepiandrosterone-sulphate (DHEA-S) and 17 alpha-hydroxyprogesterone (170HP) while also the free androgen index (FAI) was calculated. Measurements were repeated during the 3rd week of pill intake in the 4th and the 6th pill month. There were no differences on body mass and blood pressure with the use of the four OCs. The mean serum DHEA-S decreased significantly in all groups though less in the Mercilon group when compared to Cilest and Marvelon (approximately 20% vs 45%). Mean serum SHBG and CBG increased significantly in all four groups approximately 250% and 100%, respectively. In each group CBG also increased significantly but less in women taking Mercilon (-75%) as compared to the others (-100%). Current low-dose OCs were found to have similar impact on the endogenous androgen metabolism with significant decreases of serum testosterone, DHT, A, and DHEA-S. They may be equally beneficial in women with androgen related syndromes such as acne and hirsutism. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/8689882/Changes_in_androgens_during_treatment_with_four_low_dose_contraceptives_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0010782496000066 DB - PRIME DP - Unbound Medicine ER -